Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Dec;64(12):5395–5398. doi: 10.1128/iai.64.12.5395-5398.1996

Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G.

A Norrby-Teglund 1, R Kaul 1, D E Low 1, A McGeer 1, J Andersson 1, U Andersson 1, M Kotb 1
PMCID: PMC174535  PMID: 8945593

Abstract

Recently we demonstrated that normal polyspecific immunoglobulin given intravenously (IVIG) and plasma samples from patients treated with IVIG neutralize the mitogenic and cytokine-inducing activities of group A streptococcal (GAS) superantigens. Here we investigated whether this neutralizing activity is mediated by antibodies to these superantigens. IVIG and plasma samples collected from a patient with GAS necrotizing fasciitis post-IVIG infusions markedly inhibited the mitogenic activity elicited by the streptococcal pyrogenic exotoxins SpeB and SpeC, as well as by GAS culture supernatant. Immunoblot analysis showed marked increases in the levels of antibodies to SpeC and proteins in the GAS culture supernatant in post-IVIG over those of pre-IVIG plasma samples. Removal of antisuperantigen antibodies in IVIG by adsorption to SpeC- and GAS culture supernatant-coupled Sepharose markedly reduced the neutralizing ability of IVIG against respective stimuli. The neutralizing activity was totally recovered in the eluted antibodies. By contrast, although pre- and post-IVIG plasma samples contained antibodies to SpeA, these antibodies did not block the activity of this superantigen. Nonspecific immunomodulatory activity of IVIG was ruled out because neither the IVIG nor the affinity-purified antibodies significantly inhibited the response to the polyclonal T-cell mitogen phytohemagglutinin A. These data provide direct evidence that the neutralizing activity in IVIG, and in patient plasma samples following IVIG treatment is mediated by antibodies to superantigens and indicate that the quality rather than the quantity of these antibodies may be more clinically relevant.

Full Text

The Full Text of this article is available as a PDF (180.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry W., Hudgins L., Donta S. T., Pesanti E. L. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA. 1992 Jun 24;267(24):3315–3316. [PubMed] [Google Scholar]
  2. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev. 1995 Jul;8(3):411–426. doi: 10.1128/cmr.8.3.411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Marrack P., Kappler J. The staphylococcal enterotoxins and their relatives. Science. 1990 May 11;248(4956):705–711. doi: 10.1126/science.2185544. [DOI] [PubMed] [Google Scholar]
  4. Mollick J. A., Miller G. G., Musser J. M., Cook R. G., Grossman D., Rich R. R. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J Clin Invest. 1993 Aug;92(2):710–719. doi: 10.1172/JCI116641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Nadal D., Lauener R. P., Braegger C. P., Kaufhold A., Simma B., Lütticken R., Seger R. A. T cell activation and cytokine release in streptococcal toxic shock-like syndrome. J Pediatr. 1993 May;122(5 Pt 1):727–729. doi: 10.1016/s0022-3476(06)80014-4. [DOI] [PubMed] [Google Scholar]
  6. Norrby-Teglund A., Kaul R., Low D. E., McGeer A., Newton D. W., Andersson J., Andersson U., Kotb M. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol. 1996 Apr 15;156(8):3057–3064. [PubMed] [Google Scholar]
  7. Norrby-Teglund A., Newton D., Kotb M., Holm S. E., Norgren M. Superantigenic properties of the group A streptococcal exotoxin SpeF (MF). Infect Immun. 1994 Dec;62(12):5227–5233. doi: 10.1128/iai.62.12.5227-5233.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Norrby-Teglund A., Pauksens K., Holm S. E., Norgren M. Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J Infect Dis. 1994 Sep;170(3):585–591. doi: 10.1093/infdis/170.3.585. [DOI] [PubMed] [Google Scholar]
  9. Schlievert P. M. Role of superantigens in human disease. J Infect Dis. 1993 May;167(5):997–1002. doi: 10.1093/infdis/167.5.997. [DOI] [PubMed] [Google Scholar]
  10. Skansén-Saphir U., Andersson J., Björk L., Andersson U. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur J Immunol. 1994 Apr;24(4):916–922. doi: 10.1002/eji.1830240420. [DOI] [PubMed] [Google Scholar]
  11. Stevens D. L. Invasive group A streptococcus infections. Clin Infect Dis. 1992 Jan;14(1):2–11. doi: 10.1093/clinids/14.1.2. [DOI] [PubMed] [Google Scholar]
  12. Takei S., Arora Y. K., Walker S. M. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]. J Clin Invest. 1993 Feb;91(2):602–607. doi: 10.1172/JCI116240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Watanabe-Ohnishi R., Low D. E., McGeer A., Stevens D. L., Schlievert P. M., Newton D., Schwartz B., Kreiswirth B., Kotb M. Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project. J Infect Dis. 1995 Jan;171(1):74–84. doi: 10.1093/infdis/171.1.74. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES